IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-4.16%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

Opus Genetics, Inc. (IRD) filed a Form 8-K on June 13, 2025, reporting the entry into a Material Definitive Agreement. The Company is a biotechnology firm focused on developing gene therapies, specifically for retinitis pigmentosa caused by MERTK gene variants.

Key Financial Metrics

This filing does not report standard financial statements such as revenue, profit, cash flow, or margins. The primary financial impact is a non-dilutive funding agreement with the Foundation Fighting Blindness Retinal Degeneration Fund (RDF).

  • Total Funding Available: Up to $2,000,000.
  • Initial Disbursement: $1,000,000 to be received in the near future.
  • Milestone Disbursement: Up to $1,000,000 contingent on achieving specified development milestones and RDF receiving eligible funds.
  • Debt/Liquidity Impact: The funding is non-dilutive, meaning it does not require the issuance of new equity.

Material Changes and Agreement Terms

The Company entered into a funding agreement to support the MERTK Program. Key terms include:

  • Diligence Obligations: The Company must meet development milestones; failure to do so may require collaboration with RDF to out-license rights to a third party.
  • Regulatory Milestone Payment: Upon achieving a regulatory milestone, the Company must pay RDF an amount equal to the total funds disbursed.
  • Royalties: Tiered royalty payments in low-to-mid single-digit percentages until RDF receives aggregate royalties equal to 300% of the funded amounts.
  • Change of Control: In the event of a sale or exclusive license of the program, RDF may require a buyout of its interest equal to 100% of funds disbursed.

Guidance, Risks, and Contingencies

The filing does not provide updated financial guidance or management commentary on overall company outlook. Specific risks and contingencies identified include:

  • Performance Risk: Failure to meet diligence obligations or milestones could trigger out-licensing of the MERTK Program.
  • Future Cash Outflows: The Company faces future obligations for milestone payments and royalties based on the success of the program.
  • Termination: The agreement may be terminated by either party for cause, including material breach or bankruptcy.

Investor Verification Checklist

  • Verify the exact timing of the initial $1,000,000 disbursement.
  • Review the specific development milestones required to unlock the remaining $1,000,000.
  • Confirm the definition of the "regulatory milestone" that triggers the repayment obligation.
  • Monitor the upcoming Form 10-Q for the quarter ended June 30, 2025, for the full text of the Agreement.